Neoadjuvant Treatment of Borderline Resectable Pancreatic Cancer

Neoadjuvant Treatment of Borderline Resectable Pancreatic Cancer

Borderline resectable pancreatic ductal adenocarcinoma accounts for approximately 20% of newly diagnosed pancreatic cancer patients. This type of adenocarcinoma is between resectable and unresectable. It has a high degree of heterogeneity and features in anatomy, biology, and physical condition. The...

Full description

Bibliographic Details
Main Authors: CHEN Zegang, WANG Yongbing, OU Tao
Format: Article
Language:zho
Published: Magazine House of Cancer Research on Prevention and Treatment 2022-09-01
Series:Zhongliu Fangzhi Yanjiu
Subjects:
pancreatic ductal adenocarcinoma
borderline resectable pancreatic cancer
neoadjuvant therapy
operation
chemotherapy
radiotherapy
Online Access:http://www.zlfzyj.com/EN/10.3971/j.issn.1000-8578.2022.22.0064

Similar Items

Similar Items